RE:RE:Buyout PoolONCY has $500 million in R&D write-offs and the potential of $US 2.4 Billion in peak annual sales for the 3rd line HR+/HER2- breast cancer alone, and with 13 years of FDA market exclusivity from the approval date of pelareorep.
And then there are 2 indications in PDAC, followed by anal cancer, TNBC, CRC and GI cancer indications as follow-on approvals.
So US$ 500 million would just cover the R&D costs that are still on the books.